Nanoparticles enhance drug solubility, stability, and bioavailability, improving therapeutic outcomes for GI conditions like IBD through targeted delivery mechanisms. Hydrogel-based systems offer ...

Here are seven gastroenterology drugs and technologies that have been approved or cleared by the FDA in the past five months: 1. Voquezna Triple Pak and Voquezna Dual Pak, which both treat ...

Please provide your email address to receive an email when new articles are posted on . There were several important FDA approvals for GI conditions over the past year, including the first treatment ...

A rise in popularity in glucagon-like peptide 1 receptor agonists such as Ozempic and Wegovy is causing concern in the medical community over potential side effects for various physician specialties, ...

NEW YORK (Reuters Health) - A drug from the class of antidepressants called selective serotonin reuptake inhibitors (SSRIs), such as Prozac, Zoloft or Paxil, added to a nonsteroidal anti-inflammatory ...

Ironwood Pharmaceuticals, a company whose drug research yielded a blockbuster gastrointestinal disorder drug, has struck a $1 billion deal to acquire VectivBio, a biotech whose lead program brings ...

Among the most recently approved drugs for weight management, glucagon-like peptide 1 (GLP-1) agonists have garnered considerable attention; however, the effects of these drugs on the gastrointestinal ...

"Those effects themselves are not usually severely dangerous, but there are some patients who have very severe vomiting, ...

When used as a weight-loss tool, the glucagon-like peptide-1 (GLP-1) receptor agonists semaglutide (Ozempic) and liraglutide (Saxenda), both sold by Novo Nordisk, raise the odds that patients will ...

NEW YORK (Reuters Health) - Although all of the common strategies protect the upper gastrointestinal tract from the complications of nonsteroidal anti-inflammatory drugs (NSAIDs), popular ...

Please provide your email address to receive an email when new articles are posted on . Gastroenterology had a big year in 2022, with potentially game-changing FDA approvals for inflammatory bowel ...